Assessing Tandem Diabetes Care's Valuation After Legal Probe and Pump Correction Announcement

Tandem Diabetes Care's (TNDM) valuation is being reassessed after a voluntary correction of certain t:slim X2 insulin pumps and a legal probe. Despite a 30-day share price return of 36.63% and 90-day gain of 58.35%, the 1-year total shareholder return is negative 39.22%. The company's product pipeline, including the upcoming launches of Steadiset and Tubeless Mobi, reinforces innovation leadership and supports topline growth and gross margin expansion. However, competition and execution risk around Tandem's commercial transformation could derail these improvements.